BioSpace News Archive

IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in veterinary diagnostics and software, announced today the launch of the ProCyte One™ Hematology Analyzer

Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, announced its financial results for the quarter ended June 30, 2020 and provided a business update.

Arcadia Biosciences, Inc. ® (Nasdaq: RKDA), a leader in science-based approaches to enhancing the quality and nutritional value of crops and food ingredients, today announced a collaboration with GoodMill

Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture and commercialization of innovative diagnostic and therapeutic agents and products, today announced the U.S. Food and Drug Admi

Applied DNA Sciences, Inc. (NASDAQ: APDN) (“Applied DNA” or the “Company”) a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing for product authenticity and traceability solutions, announced today that it has received a Notice of Allowance for its U.S. Patent Application No. 14/572,552 (US 2016/0168781 A1) enti

Seattle Genetics Announces TUKYSA ® (tucatinib) Approved Within Months for All Countries Participating in FDA’s Project Orbis Initiative - Australia Joins U.S., Switzerland, Canada and Singapore in Approval of TUKYSA for the Treatment of Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer -

Halberd Corp. (OTC PINK:HALB) today announced the addition of Edson Brito to the Scientific Advisory Board. Mr. Brito is CEO and Chief Business Development Officer of Cellybri Advanced Therapies in Brazil.

Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a plasma-derived biopharmaceutical company, today announced financial results for the three and six months ended June 30, 2020.

Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the second quarter ended June 30, 2020 and provided a clinical and corporate update.

MediRevv, a leading Iowa-based revenue cycle management company, announced it has assumed the rank of No. 1935 in Inc. Magazine’s annual Inc. 5000 list—the most prestigious ranking of the nation’s fastest-growing private companies